- Details
- Sia Daneshmand discusses a study published in European Urology which evaluated the atypical cytologies to evaluate the performance of Cxbladder diagnostic tests to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma. Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information. Biography: Siamak (Sia) Daneshmand,...
|
- Details
- (Length of Discussion: 10 min) Ashish Kamat and Alicia Morgans discuss the highlights of his presentation at LUGPA 2018, on the evolution of technology and technique when treating bladder cancer. The initial resection of the bladder is paramount to the path of management for these patients, including the type of anesthesia, angles of scopes, white light and blue light detection, narrow-band imagin...
|
- Details
- Alexander Wyatt from the University of British Columbia joins Ashish Kamat in a discussion on the genomic correlates of Bacillus Calmette-Guerin (BCG) responsive and relapsed non-muscle invasive bladder cancer. Dr. Wyatt shares recent study findings exploring links between common genomic driver alternations and BCG unresponsiveness and also data looking at genomic variables in the context of initi...
|
- Details
- Angela Smith reviews the patient reported outcomes (PROs) outlined in the article "Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer". Angela’s discussion includes how these PROs are incorporated into clinical practice and into the management of bladder cancer patients. Biography: Angela B. Smith, MD, MS, Assistant Professor, Department of Surgery/Urology UNC...
|
- Details
- In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease space, specifically patients with high-risk carcinoma in situ, with or without papillary tumors that had become unresponsive to Bacillus Calmette-Guerin (BCG) based on the current Federal Drug Adminis...
|
- Details
- Michael O'Donnell shares his insight into managing the current BCG shortage crisis, highlighting ways to make the most out of the current supply and explains a few alternative intravesical agents that could be used in place of BCG for treating patients with bladder cancer. Dr. O'Donnell explains how risk can be assessed while prioritizing high-risk patients and shares advice as to how treatment pl...
|
- Details
- Recorded Date: April 18, 2020 Many of the tests used to diagnose and detect bladder cancer involve invasive procedures. Non-invasive testing options are equally effective and can be applied in this COVID-19 environment where we want to limit patients needing to come into the clinics for tests. In this discussion Neal Shore, Sima Porten, and Tom Nifong discuss Cxbladder a non-invasive, urine-based...
|
- Details
- Ashish Kamat welcomes leading bladder cancer experts Paolo Gontero and Bernard Bochner to engage in a debate considering a hypothetical patient with nonmuscle invasive high-grade T1 disease. Dr. Bochner starts by addressing different treatment options for patients presenting with T1 disease while acknowledging that T1 disease is a spectrum and can be variably invasive. He discusses BCG as a treatm...
|
- Details
- Joshua Meeks joins Alicia Morgans to discuss the current BCG shortage and its implications for treatment options in the bladder cancer community. Dr. Meeks highlights clinical data on the matter presented by other clinicians at the conference, as well as his own personal expertise on how he manages the patient selection and the risk stratification process for BCG resources in his own clinic. Biogr...
|
- Details
- Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma (UC). In this video presentation, Badrinath Konety overviews this study which aimed to evaluate the performance of Cxbladder and urine cytology and Cxbladder's adjudication of atypical cytology and e...
|
